Photo from wikipedia
trial. Lancet Respir Med 2021;9:57–68. 8. Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. Optimal asthma control: time for a new target. Am J Respir Crit… Click to show full abstract
trial. Lancet Respir Med 2021;9:57–68. 8. Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. Optimal asthma control: time for a new target. Am J Respir Crit Care Med 2020;201:1480–1487. 9. Pavord ID, BeasleyR, Agusti A, AndersonGP, Bel E, Brusselle G, et al.After asthma: redefining airways diseases. Lancet 2018;391:350–400. 10. Patel M, Pilcher J, Reddel HK, Qi V, Mackey B, Tranquilino T, et al.; SMART Study Group. Predictors of severe exacerbations, poor asthma control, and b-agonist overuse for patients with asthma. J Allergy Clin Immunol Pract 2014;2:751–758. 11. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, et al. Effect of a single day of increased as-needed budesonideformoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med 2021;9:149–158.
Journal Title: American Journal of Respiratory and Critical Care Medicine
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!